-
The Medical Letter on Drugs and... May 1986
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; Heart Diseases; Heart Ventricles; Humans; Kinetics; Pulmonary Fibrosis
PubMed: 3702807
DOI: No ID Found -
Critical Care Nurse 1986
Topics: Amiodarone; Arrhythmias, Cardiac; Hemodynamics; Humans
PubMed: 3641704
DOI: No ID Found -
Annals of Medicine Feb 2012Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Until recently, a rhythm control strategy for AF has been limited by drug... (Comparative Study)
Comparative Study Review
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Until recently, a rhythm control strategy for AF has been limited by drug toxicity and side-effects, and landmark AF trials have shown that such a strategy is not superior to a rate control one. New antiarrhythmic drugs, free of undesired effects, would enhance the rhythm control strategy, with the possibility of sinus rhythm restoration and maintenance. One of the promising drugs recently approved for clinical use is dronedarone. This drug has amiodarone-like antiarrhythmic and electrophysiological properties, despite it having a modified structure and lacking an iodine moiety. Thus, dronedarone lacks amiodarone's organ toxicity (including adverse thyroid and pulmonary effects). The efficacy of dronedarone has been investigated in several clinical trials, proving its effect in the prevention of AF recurrence, rate control in paroxysmal/persistent and permanent AF, reduction of cardiovascular hospitalization or death from any cause, and others. Indirect comparisons with amiodarone, as well as one head-to-head study of the two drugs, indicate that the relative safety of dronedarone may be at a cost of its lower antiarrhythmic efficacy compared with amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; Humans; Treatment Outcome
PubMed: 21745093
DOI: 10.3109/07853890.2011.594808 -
Methods and Findings in Experimental... Jan 1984
Review
Topics: Amiodarone; Benzofurans; Bile; Body Fluids; Chemical Phenomena; Chemistry, Physical; Drug Interactions; Humans; Intestinal Absorption; Kinetics; Liver; Tissue Distribution
PubMed: 6371407
DOI: No ID Found -
Deutsche Medizinische Wochenschrift... Jan 1990
Review
Topics: Amiodarone; Dose-Response Relationship, Drug; Half-Life; Heart; Humans; Time Factors
PubMed: 2404728
DOI: 10.1055/s-2008-1064978 -
Annals of Internal Medicine May 1995To review the pharmacology, electrophysiology, and toxicity of amiodarone and to discuss the clinical results produced when amiodarone is used as therapy for patients... (Review)
Review
PURPOSE
To review the pharmacology, electrophysiology, and toxicity of amiodarone and to discuss the clinical results produced when amiodarone is used as therapy for patients with atrial fibrillation, patients with nonsustained ventricular tachycardia and cardiomyopathy, patients who have recently had myocardial infarctions, and patients who have survived out-of-hospital cardiac arrest caused by ventricular tachycardia or ventricular fibrillation.
DATA SOURCES
Animal and clinical studies involving the pharmacology and electrophysiology of amiodarone and clinical trials in which amiodarone was used as therapy for the arrhythmias noted above were reviewed.
STUDY SELECTION
Relevant studies that reported on the efficacy and toxicity of amiodarone and on long-term therapy using amiodarone were reviewed, and their data were summarized. Reports of ongoing trials using amiodarone were also reviewed and summarized.
RESULTS
Amiodarone is useful for the treatment of many rhythm disturbances. Although side effects from this agent are common, serious toxicity necessitating discontinuation of therapy is infrequent. Unlike other antiarrhythmic agents, amiodarone has not been shown to increase mortality in any population studied.
CONCLUSION
Amiodarone, a unique antiarrhythmic agent with many pharmacologic actions, is effective in the treatment of a wide range of rhythm abnormalities. Several large, randomized trials will provide further information about the clinical usefulness of this agent.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Electrophysiology; Heart; Hemodynamics; Humans
PubMed: 7702232
DOI: 10.7326/0003-4819-122-9-199505010-00008 -
Journal de Pharmacie de Belgique Mar 2016
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Stability; Glucose; Humans; Infusions, Intravenous; Isotonic Solutions
PubMed: 30281220
DOI: No ID Found -
Clinical Pharmacokinetics Jun 1988
Review
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Child; Dose-Response Relationship, Drug; Humans; Monitoring, Physiologic; Time Factors
PubMed: 3293869
DOI: 10.2165/00003088-198814060-00001 -
Cardiac Electrophysiology Clinics Jun 2016Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF). It is a multi-channel... (Review)
Review
Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF). It is a multi-channel blocker with diverse electrophysiologic properties. Dronedarone decreases the incidence of AF recurrence and the ventricular rate during recurrence. Dronedarone decreases rates of cardiovascular hospitalizations in patients with paroxysmal and persistent AF. Dronedarone increases mortality in patients with permanent AF and those with moderate-severe heart failure, and should thus be avoided in these populations. Dronedarone is less effective than amiodarone but also has less toxicity. Direct comparison with other antiarrhythmic drugs is not available.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans
PubMed: 27261834
DOI: 10.1016/j.ccep.2016.02.008 -
Journal of Clinical Pharmacology May 1989
Topics: Amiodarone; Humans
PubMed: 2738174
DOI: 10.1002/j.1552-4604.1989.tb03348.x